Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4SFKW)

• Drug Name: Org-36764 Drug Info
• Synonyms: 175890-65-0; ORG-38793; Org-36653; Org-36654; Org-36708

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DM4SFKW

Molecule-Related Drug Atlas

Drug(s) Targeting Antithrombin-III (ATIII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[2]
Heparin Calcium	DMEVXY6	Coagulation defect	3B10.0	Approved	[2]
Sulodexide	DMNUC42	Tinnitus	MC41	Approved	[3]
Heparin Sodium	DM9KHZL	Coagulation defect	3B10.0	Approved	[4]
Unfractionated heparin	DMCWM03	Thrombosis	DB61-GB90	Phase 3	[5]
Heparin low molecular weight	DMGFULM	Thrombosis	DB61-GB90	Phase 3	[6]
KW-3357	DMP3GI2	Coagulation defect	3B10.0	Phase 3	[7]
O-desulfated heparin	DMJL4A7	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
M118	DML0I2Z	Acute coronary syndrome	BA41	Phase 2	[9]
PMX-60056	DMWT73D	Coagulation defect	3B10.0	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Antithrombin-III (ATIII)	TT4QPUL	ANT3_HUMAN	Modulator	[1]

References

• [1] Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities. Thromb Haemost. 2000 Oct;84(4):611-20.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
• [5] Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97.
• [6] Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8.
• [7] Company report (kyowa-kirin)
• [8] Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8.
• [9] Clinical pipeline report, company report or official report of Momentapharma.
• [10] Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721.